This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000mg/m2 day 1 & 8 and Irinotecan 100 mg/m 2 day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10) experienced partial response and 14 (70) experienced stable disease. The median time to disease progression was 4 months (95 CI: 2.86.6). The 1 year and 2 year survival rates were 36 and 27, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.
- Angiogenesis inhibitor
- Thalidomide, non small cell lung cancer
ASJC Scopus subject areas
- Cancer Research